Yancopoulos, Regeneron’s chief scientific officer ... variable region gene segments at endogenous mouse immunoglobulin loci. These mice contain the “full repertoire” of human heavy chain ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

A large interdisciplinary team of researchers has found that as mice age, levels of a certain type of immunoglobulin escalate ...

Regeneron (REGN) Pharmaceuticals announced new and updated ... and a pioneering combination of a monoclonal antibody and small interfering RNA, siRNA. Progress on the odronextamab development program ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Dupixent, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential ... been validated in animal studies which found that mice genetically engineered to lack copies of the GPR75 ...

Regeneron Pharmaceuticals Inc. released data recently showing that its antibody cocktail boosted ... to knock out the myostatin-creating gene in mice; Yancopoulos called the resulting rodents ...